- Healthcare Mixed Signals, Oct 26Biotech and AI advances offer fresh upside while policy and affordability pressures create headwinds. Today’s briefing breaks down the Moderna update, Medicare access risk, and research milestones.
- Healthcare Momentum After ESMO and Vaccine News - Oct 25ESMO showcases and a landmark cancer vaccine success are driving positive momentum in healthcare. Research on brown fat and care-access issues add nuance as markets head into the long weekend.
- Healthcare Momentum: Cancer Vaccine, RNAi, More - Oct 25Breakthrough cancer vaccine data from Moderna and Merck drove optimism heading into the long weekend. Clinical wins, diagnostic advances, and fresh funding keep healthcare in focus for investors on Oct 25.
- Healthcare Sector Wrap - Oct 24Clinical wins, diagnostic advances and fresh capital drove positive headlines for healthcare heading into the long weekend. Read what matters for drug developers, diagnostics players and providers as markets reopen on Monday.
- Healthcare Roundup Oct 24A mixed day in healthcare as Ebola response accelerates while cancer vaccine and RNAi advances show promise. Regulators, safety signals and policy fights will shape momentum heading into next week.
- Healthcare Wrap: Trials, Policy, Funding Oct 23Today's healthcare headlines mixed breakthroughs in cancer research and cell therapy with safety and policy headwinds. Funding and operational reforms kept momentum but legal and trial risks stayed front and center.
- Healthcare Faces Coverage Crunch - Oct 23Federal and state policy moves on Medicaid and Medicare dominate the healthcare narrative today, threatening coverage for many while research and a $318M IPO provide isolated upside. Here’s what you need to know before the market opens.
- Healthcare: Breakthroughs and M&A - Oct 22Clinical breakthroughs and strategic deals drove healthcare headlines on Oct 22. A 42% melanoma risk reduction, zero recurrences in a colon cancer cohort, new AI and gene‑editing progress, plus M&A and FDA activity shaped sector momentum.
- Healthcare Faces Multiple Headwinds - Oct 22An Ebola outbreak that has crossed borders and rising employer premiums headline today's healthcare briefing. Policy shifts on rural funding and mental-health access issues add to sector uncertainty.
- Healthcare Gains After Approvals, M&A — Oct 21Big clinical wins and deal activity drove healthcare headlines today, led by GSK and Ionis FDA approval and Roivant and Arcus data. You get clearer near-term catalysts and policy headwinds to watch.
- Healthcare Morning Briefing - Oct 21Clinical wins and policy pressure shaped the healthcare tape overnight. A surprise bipolar trial success and manufacturing talk from Mark Cuban contrast with affordability and access headwinds that could keep volatility high.
- Healthcare Mixed Signals Amid Research, Policy - Oct 20Clinical and AI advances today were tempered by pricing and regulatory concerns. New study wins and a bipolar trial surprise sit alongside ICER price warnings and tougher Medicaid oversight.
- Healthcare Headlines: Trials, Policy, Screening - Oct 20Clinical advances and trial rebounds lead healthcare news on Oct 20, while policy fights and vendor scrutiny keep risks in view. Read what matters for your watchlist and catalysts to track today.
- Healthcare: M&A, Trial Wins, Policy Moves - Oct 19M&A and partnership activity led the healthcare tape on Oct 19, with Merck KGaA's $1.3B RNAi buyout and Roche's $15B ADC pact drawing attention. Clinical wins and a new NIH women’s health push add momentum, while access and legal issues keep risk on the radar.
- Healthcare Momentum Shifts to AI and R&D - Oct 19Gilead reports promising mid‑stage results while AI tools for EHRs and payer intelligence gain traction. You’ll want to weigh clinical wins against regulatory and hype risks today.
- Healthcare Wrap: Surgery Studies & Lawsuit - Oct 18New anesthesia-era studies show GLP-1 drugs may cut postoperative heart events while cannabis use links to higher perioperative heart attack risk. A jury verdict adds reputational risk for research institutions. Read what this means heading into Oct 19.
- Healthcare Momentum and Risks - Oct 18Diagnostic imaging breakthroughs, an AI drug IPO, and rising interest in longevity clinics are driving sector momentum heading into next week. You should weigh innovation-driven upside against policy and cost pressures.
- Healthcare Mixed Signals - Oct 17 WrapClinical wins for diabetes tech and perioperative care share headlines with an AI drug IPO, Moderna’s run, and policy and access headwinds. Here’s what you need to know heading into Oct. 19.
- Healthcare Momentum: AI IPOs & Alzheimer Imaging - Oct 17Heading into the long weekend, healthcare shows momentum as an AI drug IPO and expanding Alzheimer PET use join a biotech rally. Legal and policy risks remain on the radar.
- Healthcare Roundup: IPOs, Policy & Research - Oct 16A mixed day for Healthcare: an AI drug developer's $150M IPO and Moderna's 2026 run contrast with regulatory fights over peptides and ACA broker rules. Research in imaging and tumor metabolism adds longer-term catalysts.
- Healthcare: Policy Strains and M&A Moves - Oct 16Today’s Healthcare briefing covers policy turbulence around ACA and Medicaid, Zocdoc’s first acquisition, a revival of CAR-T research tied to Galapagos assets, and new clinical and public health findings. Read what catalysts and risks could move the sector today and what you should watch next.
- Healthcare Faces Innovation and Oversight - Oct 15Today's healthcare news mixes big-science momentum with tougher oversight and access questions. From Merck and Moderna's cancer vaccine plans to FDA rare-disease changes and DOJ crackdowns, here's what you need to know.
- Healthcare: Policy, Research & IPOs - Oct 15A KFF probe into hospital financial aid and a CDC survey on teen binge eating set policy and social risk tones, while AI drug discovery startup Iambic raises $150M in an IPO. Read what you should monitor today.
- Healthcare Wrap-Up - Oct 14Today brought a blend of scientific breakthroughs, insurer policy shifts and legal headlines. You’ll find what moved the sector, which companies were in the spotlight, and what to watch next.
- Healthcare Morning Briefing - Oct 14WHO says an Ebola vaccine trial will start in DR Congo by end of October while states, lobbyists and researchers press on AI, vaccine policy, reproductive science and biotech deals. Read what you should watch today.
- Healthcare Wrap: Deals, Trials — Oct 13Big deal-making and public-health guidance stood out today, while an mRNA cancer candidate missed a key trial milestone. Read what moved the sector, what to watch next, and how policy and trials may shape stocks.
- Healthcare Morning Brief, Oct 13Biotech data and safety debates set the tone in healthcare on Oct 13. You’ll want to track Neurocrine safety scrutiny, First Tracks study strength, and policy moves on kids’ online safety.
- Healthcare Mixed Signals, Research & Policy in Focus - Oct 12Today’s healthcare news was a mixed bag: new lab breakthroughs and an IPO filing contrasted with trial disappointment, policy fights, and workforce stress. Here’s what moved the sector and what you should watch next.
- Healthcare Sector Snapshot - Oct 12Workforce stress and public trust weigh on healthcare, while new microbiome and psychedelic research offers scientific upside. Read what matters for markets and what you should watch today.
- Healthcare Roundup - Oct 11Policy and public-health research shared the spotlight this weekend. New studies on celiac biomarkers, childhood lead mapping, and parenting sit alongside renewed 340B litigation and federal leadership shifts, leaving the sector with mixed signals heading into Monday.
- Healthcare Faces Policy and Biotech Headwinds - Oct 11Policy fights and fresh biotech headwinds set the tone heading into the week, even as new prevention and nutrition studies landed. Read what you need to know for the week ahead.
- Healthcare Sector Wrap Oct 10Research advances in AI safety and early-onset Alzheimer’s offer long-term upside, while biotech data disappointments, policy fights and prescribing concerns keep near-term risk elevated. Markets were closed on Saturday; here’s what to watch heading into Monday.
- Healthcare Mixed Signals Ahead of Long Weekend - Oct 10Biotech headlines and policy fights created pressure while Medicare Advantage results delivered winners and losers. Read what to watch heading into the long weekend and next week.
- Healthcare Evening Wrap — Oct 9Biotech faced pressure as FDA disclosures sparked a sell-off while a $117M IPO and Humana's star-rating win provided offsets. Read the day's implications and what you should watch next.
- Healthcare Morning Briefing - Oct 9Today’s healthcare headlines mix deal activity with public health and policy risks. You’ll want to track Viatris’s $1.7B Pacira deal, AI lobbying at CMS, and mounting security and public health threats.
- Healthcare Mixed Signals on Funding, M&A - Oct 8Today’s healthcare news was a mixed bag: a $1.7B pain-drug deal and promising clinical research were offset by NIH funding uncertainty, an Argenx trial stoppage, and security risks. Read what you should watch next.
- Healthcare Sector Snapshot - Oct 8Mixed healthcare headlines mark the morning of Oct 8: new infectious disease research and policy debates are balanced by biotech funding pain and potential hospital reimbursement changes. Read what you should watch today.
- Healthcare Faces Legal Headwinds - Oct 7Lawsuits, a Dutch court ruling against Merck and a probe into UnitedHealth set a cautious tone for healthcare today. Biotech funding strains and company layoffs add pressure despite new scientific findings.
- Healthcare: Funding, Policy & Setbacks - Oct 7Today’s healthcare headlines show mixed signals: large biotech fundraising and promising research sit alongside a CAR-T developer shutdown and sharp SNAP enrollment drops. Read what you should watch and how policy, innovation and capital flows could affect the sector.
- Healthcare Wrap: Big Wins and Setbacks - Oct 6A landmark lymphoma readout and a major venture fundraise competed with a painful clinical setback and regulatory pressure on hospitals. Today’s moves underline selective opportunity and near-term risks in healthcare.
- Healthcare Roundup - Oct 6M&A and a Nobel prize brighten the tape, but worries about diagnostics, screening tests and a large measles outbreak keep the sector cautious. Read what you should watch today.
- Healthcare Wrap: Vaccine Wins and Policy Shifts - Oct 5Biotech momentum led the Healthcare sector today as Vaxcyte's pneumococcal data and a $2B rare-disease deal dominated headlines. Policy moves on price transparency and new AI pilots add regulatory angles you should watch.
- Healthcare Innovates After Nobel Win - Oct 5A 2026 Nobel for optogenetics spotlights neuroscience tools while AI, manufacturing and diagnostics stories reinforce innovation-driven momentum in healthcare. Read what to watch today.
- Healthcare Wrap-Up: Research Meets Policy - Oct 4Policy moves and new nutrition and vascular research shaped healthcare headlines over the weekend. Today’s stories point to longer-term clinical trends and short-term political risk ahead of the Nov 3 midterms.
- Healthcare Roundup: Deals, Science, and Policy - Oct 4A big RNA deal, new drug targets from parasite mitochondria maps, and fresh neuroscience data headline a busy healthcare weekend. You’ll want to track deal structures, policy shifts, and upcoming catalysts heading into Oct 5.
- Healthcare: Deals, Research & Policy - Oct 3Novartis's multi-billion dollar RNA pact and new parasite and tau research highlight momentum in drug discovery, while policy shifts and treatment-access stories add nuance. Heading into the long weekend, select biotech names merit watching.
- Healthcare Snapshot - Oct 3Outbreaks in food and Florida dengue dominate public-health headlines, while Novartis struck a major RNA deal with Abogen. Read what you should watch heading into the long weekend.
- Healthcare Wrap: Deals, Data and Policy - Oct 2Big pharma dealmaking and public-health gains balanced policy and payer headwinds today. You’ll find what moved the sector, what to watch next, and how these stories could affect market sentiment tomorrow.
- Healthcare Morning Briefing - Oct 2Clinical advances in diabetes remission and a superior RNA urine test headline a mixed morning for healthcare. Policy shifts around 340B, NIH grant delays, and access failures keep investor focus split.
- Healthcare Highlights, Oct 1: Drugs, AI, BioprintingToday’s healthcare news mixed major corporate deals and scientific advances with policy and privacy headwinds. Read how bioprinting, alpha-therapy imaging, obesity data and 340B updates could shape the sector tomorrow.